Search
Phenelzine
go.drugbank.com/drugs/DB00780ApprovedInvestigationalPhenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA ap...
Categories: Cytochrome P-450 CYP2E1 Inducers, Cytochrome P-450 CYP2C19 InhibitorsTripelennamine
go.drugbank.com/drugs/DB00792ApprovedVet approvedA histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various r...
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsPrimidone
go.drugbank.com/drugs/DB00794ApprovedVet approvedPrimidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 Ma...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InducersMinaprine
go.drugbank.com/drugs/DB00805ApprovedMinaprine is a psychotropic drug which has proved to be effective in the treatment of various depressive states. Like most antidepressants minaprine antagonizes behavioral despair. Minaprine is an amino-phenylpyridazine antidepressant re...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesPentoxifylline
go.drugbank.com/drugs/DB00806ApprovedInvestigationalPentoxifylline (PTX) is a synthetic dimethylxanthine derivative that modulates the rheological properties of blood and also has both anti-oxidant and anti-inflammatory properties. Although originally developed to treat intermittent claud...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesIndapamide
go.drugbank.com/drugs/DB00808ApprovedInvestigationalThe most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAcetazolamide
go.drugbank.com/drugs/DB00819ApprovedInvestigationalVet approvedOne of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizur...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsTadalafil
go.drugbank.com/drugs/DB00820ApprovedInvestigationalTadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy. It was first approved in 2003 by the FDA for use ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTolazamide
go.drugbank.com/drugs/DB00839ApprovedA sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Synonyms: 1-(Hexahydro-1-azepinyl)-3-p-tolylsulfonylurea, N-(p-Toluenesulfonyl)-N'-hexamethyleniminoureaCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesDonepezil
go.drugbank.com/drugs/DB00843ApprovedInvestigationalIn 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholineste...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates